Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 4Breast 4Thoracic 2Lymphoid 2Gynecologic 2CNS 2Other solid neoplasm 1Other hematologic neoplasm 1Head & Neck 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Colorectal Neoplasms 3Neoplasms 2Lung Neoplasms 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Melanoma 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Gastrointestinal Stromal Tumors 1Esophageal Squamous Cell Carcinoma 1EGFR-mutant Non-small Cell Lung Cancer 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 61Carboplatin 44Pemetrexed 31Paclitaxel 31Docetaxel 31Cisplatin 27Gemcitabine 24Nivolumab 23Erlotinib Hydrochloride 21Bevacizumab 18Ipilimumab 11osimertinib 10Drug Therapy 10atezolizumab 9Radiosurgery 9Cyclophosphamide 9Cetuximab 9Blood Specimen Collection 9durvalumab 8cemiplimab 8Radiotherapy 8budigalimab 7Fluorouracil 7Dexamethasone 7trametinib 6fludarabine 6dostarlimab 6avelumab 6Taxes 6130-nm albumin-bound paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × ribociclib × Thoracic × Clear all
NCT02292550 2020-12-17

Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.

Novartis

Phase 1 Completed
27 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02187783 2019-07-18

SIGNATURE

Novartis

Phase 2 Completed
106 enrolled 16 charts
BreastGynecologicLymphoidOther hematologic neoplasmOther solid neoplasmThoracic

Breast Neoplasms, Leukemia, Lymphoma, Mesothelioma, Neoplasms, Ovarian Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡